Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PerSurge perioperative perampanel study in progressive glioblastoma
2023-503938-52-00Phase 2Authorised
- Sponsor
- Heidelberg University Hospital
- Start
- Jan 2024
- Modality
- Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in glioblastoma (GBM) comparing Perampanel perioperative arm with Placebo perioperative arm (2 arms). Primary endpoints: Connectivity score in tumor RNA sequencing and Kinetics of T2/FLAIR signal abnormality volume. Planned start Jan 2024; status: authorised.
02
Drugs
perampanel
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2023-503938-52-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503938-52-00.